UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030570
Receipt number R000034902
Scientific Title Single-blind, multicenter clinical study of donepezil hydrochloride for dysuria in patients with Down syndrome
Date of disclosure of the study information 2018/01/04
Last modified on 2021/01/06 13:44:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Single-blind, multicenter clinical study of donepezil hydrochloride for dysuria in patients with Down syndrome

Acronym

A study of donepezil hydrochloride for dysuria in Down syndrome

Scientific Title

Single-blind, multicenter clinical study of donepezil hydrochloride for dysuria in patients with Down syndrome

Scientific Title:Acronym

A study of donepezil hydrochloride for dysuria in Down syndrome

Region

Japan


Condition

Condition

dysuria

Classification by specialty

Pediatrics Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effectiveness of donepezil hydrochloride for dysuria in patients with Down syndrome

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

Change in maximum urinary flow rate (Qmax)

Key secondary outcomes

Changes in average urinary flow rate (AFR), urinary patterns, residual urine volume, urinary frequency, frequency of urinary incontinence, defecation patterns, and activities of daily life


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Donepezil hydrochloride

Interventions/Control_2

placebo

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

12 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Age: Patients with Down syndrome aged 12 years old or above at the time when consent is obtained.
Gender: Both male and female.
Inpatients/Outpatients: Only outpatients.
Dysuria is defined as any of the following: 1) a postvoid residual urine 20% or more of voided urine volume or 50 mL or more; 2) Qmax less than -1SD (Siroky's nomogram) in uroflowmetry; and 3) urinary frequency of twice or less per day. 4)Average urinary volume more than 600ml.
Patients and their family or guardian must voluntarily give a written consent to participation in this study with full understanding after sufficient explanation.
Only patients who have been under other medical treatment for dysuria with an insufficient effect are eligible for this study.

Key exclusion criteria

Any of the following patients will be excluded:
1) those who have already taken any acetylcholinesterase inhibitor with high CNS selectivity, including Aricept
2) those with serious liver or kidney dysfunction
3) those with drug hypersensitivity
4) those who have been in remission on other medical therapy such as Urapidil
5) those who have been on treatment with other therapeutic agent(s) for dysuria
6) those who need to change therapeutic strategy within 8 weeks of the single-blind study
7) those whom principal investigator judged as inappropriate for this study.

Target sample size

48


Research contact person

Name of lead principal investigator

1st name Hiroyuki
Middle name
Last name Moriuchi

Organization

Nagasaki University Hospital

Division name

Department of Pediatrics

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki City

TEL

095-819-7298

Email

hiromori@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Tatsuro
Middle name
Last name Kondoh

Organization

The Misakaenosono Mutsumi Developmental, Medical and Welfare Center

Division name

Division of Developmental Disabilities

Zip code

859-0164

Address

570-1 Maki, Konagai-Cho, Isahaya City

TEL

0957-34-3113

Homepage URL


Email

Kontatsu0721@gmail.com


Sponsor or person

Institute

Department of Pediatrics, Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

(1) Department of Urology, Nagasaki University Hospital
(2) Department of Urology, Saga University Hospital
(3) The Misakaenosono Mutsumi Developmental, Medical and Welfare Center

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Clinical Research Review Board in Nagasaki University

Address

1-7-1 Sakamoto, Nagasaki-shi, Nagasaki-ken

Tel

095-819-7905

Email

gaibushikin@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 12 Month 18 Day

Date of IRB

2017 Year 12 Month 19 Day

Anticipated trial start date

2018 Year 02 Month 01 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 12 Month 26 Day

Last modified on

2021 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034902


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name